SCHEMBL2369229

SCHEMBL2369229

Cc1cccc(CNc2nc(CCO)nc3scc(-c4ccccc4)c23)n1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.49
LMNA P02545 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TNF P01375 1/20 0.47
MAPK1 P28482 1/20 0.47
NOD1 Q9Y239 1/20 0.47
ALDH1A1 P00352 5/20 0.44
MAPT P10636 2/20 0.44
USP2 O75604 1/20 0.42
THRB P10828 1/20 0.42
CCNC P24863 1/20 0.40
CDK8 P49336 1/20 0.40
KCNH2 Q12809 1/20 0.40
PIP4K2C Q8TBX8 1/20 0.40
KDM4E B2RXH2 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
GAA P10253 1/20 0.38
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368714 0.91 ESR1 (0.40) ESR1LMNASMN1; SMN2TNFMAPK1
SCHEMBL2368176 0.85 LMNA (0.47) ESR1LMNASMN1; SMN2TNFMAPK1
SCHEMBL2368060 0.85 TNF (0.66) ESR1LMNASMN1; SMN2TNFMAPK1
SCHEMBL2369288 0.85 ESR1 (0.48) ESR1LMNASMN1; SMN2TNFMAPK1
SCHEMBL2368333 0.85 TSHR (0.43) ESR1LMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL2368773 0.84 ESR1 (0.70) ESR1LMNASMN1; SMN2TNFMAPK1
SCHEMBL6363419 0.84 ESR1 (0.49) ESR1LMNASMN1; SMN2TNFMAPK1
SCHEMBL2368642 0.83 ESR1 (0.47) ESR1LMNASMN1; SMN2TNFMAPK1
SCHEMBL2368753 0.83 ESR1 (0.48) ESR1LMNASMN1; SMN2TNFMAPK1
SCHEMBL2369221 0.83 PRKCI (0.43) ESR1LMNASMN1; SMN2ALDH1A1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 ESR1 4494/4885LMNA 1126/4885SMN1; SMN2 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.